• Fucoidan: Decoding the Gut–Liver Axis

  2026-09-02

  Fucoidan is a sulfated α-L-fucan with established anticancer and immune-modulating activity. This article explains how new gut–liver axis evidence reframes Fucoidan research toward chemotherapy-associated liver injury, barrier function, NETs, and multidimensional assay design.

• LY2886721: A Strategic BACE1 Research Playbook

  2026-09-01

  LY2886721 offers translational researchers a potent oral BACE inhibitor for connecting BACE1 enzyme inhibition with amyloid beta reduction, biomarker movement, and synaptic-function boundaries. This article frames the compound as a controlled research tool for Alzheimer’s disease treatment research rather than as a standalone promise of clinical efficacy.

• Protease and Phosphatase Inhibitor Cocktail: EDTA-Free

  2026-09-01

  Protease and Phosphatase Inhibitor Cocktail K4006 is a 100X, EDTA-free aqueous reagent for limiting proteolysis and dephosphorylation during biological sample extraction or lysis. It is suitable when preservation of protein integrity and phosphorylation is needed without metal chelation, but it should not replace EDTA in workflows that specifically require chelation.

• PFHxS Hepatotoxicity Through PPAR Signaling

  2026-08-31

  The reference study shows that environmentally relevant PFHxS exposure can damage liver development and function in larval zebrafish through a PPAR-centered mechanism. Its combination of transcriptomics, pathology, biochemical measurements, pharmacological antagonism, and morpholino knockdown provides a useful framework for mechanistic aquatic toxicology and cellular metabolism research.

• Chrysin, NOX2, and Ferroptosis in Dry Eye

  2026-08-31

  A 2026 study links NOX2-driven oxidative stress and STING/NLRP3 inflammation to ferroptotic corneal epithelial injury in dry eye. Using transcriptomics, cell models, and benzalkonium chloride-induced dry eye mice, the authors show that chrysin improves ocular surface outcomes while suppressing lipid peroxidation, iron overload, and inflammatory signaling.

• Thermosensitive Hydrogel for Erythromycin in Keratitis

  2026-08-30

  Zheng et al. developed a thermosensitive polyhedral oligomeric silsesquioxane hybrid hydrogel that improves erythromycin solubility, ocular-surface retention, and antibacterial performance in a mouse model of Staphylococcus aureus keratitis. The study supports a formulation strategy that combines drug loading, thermogelling behavior, mucin interaction, and biocompatibility rather than relying on repeated conventional eye-drop dosing.

• IWP-2 Workflow for Wnt Pathway Research

  2026-08-29

  IWP-2 enables controlled suppression of Porcn-dependent Wnt secretion for cancer models, pathway validation, and morphology-first phenotyping. This practical guide connects dose design, apoptosis assays, and high-content cardiomyocyte profiling while clearly separating established evidence from proposed applications.

• Lopinavir: From HIV Potency to Repurposing Logic

  2026-08-28

  Lopinavir (ABT-378) combines picomolar HIV protease potency with a valuable cross-pathogen research history. This article explains how to interpret its resistance, serum, pharmacokinetic, and MERS-CoV cell-based evidence when designing antiviral assays.

• Etoposide (VP-16): Reliable Cell Assay Workflows

  2026-08-28

  This scenario-based guide explains how Etoposide (VP-16), SKU A1971, can support reproducible cytotoxicity, proliferation, and DNA damage studies. It covers cell-line-dependent potency, DMSO stock preparation, protocol controls, data interpretation, and practical vendor-selection criteria.

• RNF166, Angiomotins, and YAP in Colorectal Cancer

  2026-08-27

  A 2024 Cell Death and Disease study identifies RNF166 as an E3 ligase that recognizes tankyrase-modified angiomotins, destabilizes these Hippo-pathway regulators, and promotes YAP activation in colorectal cancer. The work connects poly-ADP-ribosylation to substrate recognition and tumor progression, while offering a framework for separating pathway mechanism from phosphorylation-sensitive sample handling.

• Rocket-Like Nanomedicine Restores PDAC Stroma

  2026-08-27

  The reference study develops an acid-responsive, multistage nanomedicine that first remodels pancreatic tumor stroma and then releases gemcitabine for improved intratumoral delivery. Its main innovation is the coordinated use of halofuginone and IPR-803 to restore stromal homeostasis, reduce angiogenic barriers, and produce marked tumor regression in a pancreatic ductal adenocarcinoma mouse model.

• HO-1–ROS Control of HBV Replication: Study Insights

  2026-08-26

  The reference study shows that isochlorogenic acid A (ICAA) suppresses hepatitis B virus replication through several coordinated effects, including reduced viral transcription, cccDNA, particle assembly, and envelopment. Its mechanistic contribution is the connection of HO-1-dependent ROS modulation with altered viral structural-protein chemistry and defective morphogenesis, while also identifying experiments needed to establish causality.

• Moxidectin B3611 for Reproducible Cell Assays

  2026-08-26

  This scenario-led guide explains how Moxidectin (SKU B3611) can be incorporated into fungal viability, proliferation, and cytotoxicity workflows without confusing assay artifacts with biological effects. It connects product handling data with recent evidence on polyene synergy in Candida albicans and provides practical controls for reproducible interpretation.

• Cefotaxime as a Genotype–Phenotype Bridge

  2026-08-25

  Cefotaxime can connect beta-lactam activity, resistance genotype, and plasmid mobility in rigorous bacterial models. This article develops an interpretation-first framework grounded in recent CREC transmission research rather than repeating standard workflow guidance.

• Sulfo-NHS-SS-Biotin for Proteostasis Assays

  2026-08-25

  Sulfo-NHS-SS-Biotin enables reversible surface protein enrichment while preserving a route to distinguish receptor trafficking from total abundance. This article connects cleavable biotinylation chemistry with the proteostasis mechanisms identified in epilepsy-associated GABAA receptor variants.

8409 records 1/561 page Next 12345 下5页 Last page